s pneumoniae strain atcc 10813 Search Results


efficacy against s pneumoniae atcc 10813  (ATCC)
94
ATCC efficacy against s pneumoniae atcc 10813
In vivo PAE of garenoxacin after administration of single doses of 16 and 64 mg/kg against S. pneumoniae ATCC 10813, S. aureus ATCC 6538p, and K. pneumoniae ATCC 43816. Each symbol represents the mean ± standard deviation for two mice. The widths of hollow bars represent the duration of time total serum levels exceeded the MIC for the infecting pathogen. The widths of the solid bars represent the duration of time free drug serum levels exceeded the MIC for the infecting pathogen.
Efficacy Against S Pneumoniae Atcc 10813, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/efficacy against s pneumoniae atcc 10813/product/ATCC
Average 94 stars, based on 1 article reviews
efficacy against s pneumoniae atcc 10813 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
pd indices  (ATCC)
99
ATCC pd indices
In vivo PAE of garenoxacin after administration of single doses of 16 and 64 mg/kg against S. pneumoniae ATCC 10813, S. aureus ATCC 6538p, and K. pneumoniae ATCC 43816. Each symbol represents the mean ± standard deviation for two mice. The widths of hollow bars represent the duration of time total serum levels exceeded the MIC for the infecting pathogen. The widths of the solid bars represent the duration of time free drug serum levels exceeded the MIC for the infecting pathogen.
Pd Indices, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd indices/product/ATCC
Average 99 stars, based on 1 article reviews
pd indices - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
strain atcc 10813  (ATCC)
97
ATCC strain atcc 10813
In vivo PAE of garenoxacin after administration of single doses of 16 and 64 mg/kg against S. pneumoniae ATCC 10813, S. aureus ATCC 6538p, and K. pneumoniae ATCC 43816. Each symbol represents the mean ± standard deviation for two mice. The widths of hollow bars represent the duration of time total serum levels exceeded the MIC for the infecting pathogen. The widths of the solid bars represent the duration of time free drug serum levels exceeded the MIC for the infecting pathogen.
Strain Atcc 10813, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/strain atcc 10813/product/ATCC
Average 97 stars, based on 1 article reviews
strain atcc 10813 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
organisms  (ATCC)
99
ATCC organisms
In vivo PAE of garenoxacin after administration of single doses of 16 and 64 mg/kg against S. pneumoniae ATCC 10813, S. aureus ATCC 6538p, and K. pneumoniae ATCC 43816. Each symbol represents the mean ± standard deviation for two mice. The widths of hollow bars represent the duration of time total serum levels exceeded the MIC for the infecting pathogen. The widths of the solid bars represent the duration of time free drug serum levels exceeded the MIC for the infecting pathogen.
Organisms, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/organisms/product/ATCC
Average 99 stars, based on 1 article reviews
organisms - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
s pneumoniae cdc  (ATCC)
85
ATCC s pneumoniae cdc
In vivo PAE of daptomycin against S. <t>pneumoniae</t> ATCC 10813 after administration of single doses of 2.5 (triangles) and 10 (squares) mg/kg. T > MIC, time that the concentration remains above the MIC.
S Pneumoniae Cdc, supplied by ATCC, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s pneumoniae cdc/product/ATCC
Average 85 stars, based on 1 article reviews
s pneumoniae cdc - by Bioz Stars, 2026-03
85/100 stars
  Buy from Supplier
s pneumoniae atcc 10813  (ATCC)
99
ATCC s pneumoniae atcc 10813
In vivo PAE of daptomycin against S. <t>pneumoniae</t> ATCC 10813 after administration of single doses of 2.5 (triangles) and 10 (squares) mg/kg. T > MIC, time that the concentration remains above the MIC.
S Pneumoniae Atcc 10813, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s pneumoniae atcc 10813/product/ATCC
Average 99 stars, based on 1 article reviews
s pneumoniae atcc 10813 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
escherichia coli o157 h7 strain  (DSMZ)
97
DSMZ escherichia coli o157 h7 strain
Microbial metabolomic pathway analysis and in vitro experiments. (A) The in vitro culture of B. longum or E. coli in the presence of excretory-secretory protein (ESP) (5 mg/ml) collected from different T. saginata tapeworm isolates ( n = 3 or 4). Colony-forming units (CFUs) were counted on plates ( n = 2 technical replicates for each sample). (B) PCoA using Bray–Curtis distance based on the relative abundances of MetaCyC pathways. (C) The pathways that were significantly increased in infection and negatively correlated with Bifidobacterium. The absolute value of the coefficient correlation between each pathway and the abundance of Bifidobacterium ( X -axis) and the coefficient in MaAsLin2 analysis (Y-axis) are shown. Only pathways with q value <0.05 in MaAsLin2 analysis were indicated with names. (D) The species with significantly differential abundance in the stachyose degradation pathway (the prevalence >0.1 and q value <0.25 after FDR correction) in MaAsLin2 analysis. The error bars indicate the 95% confidence intervals of coefficient estimates. (E) The negative correlations between B. longum and other species in the stachyose degradation pathway. The relative abundance was normalized by the centered log-ratio method. (F) In vitro growth rate of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of stachyose ( n = 3 replicates for each sample). (G) In vitro growth experiments of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of ESP ( n = 3 or 4 replicates). The data for panels A, F, and G are shown for mean ± SD, and P values for panels A and G were calculated by Student’s t -test. The R 2 statistic and P value for panel B were calculated by permutational multivariate analysis of variance (PERMANOVA). The box plot in panel B represents the 25th percentile, median, and 75th percentile and whiskers stretch to 1.5 times the interquartile range from the corresponding hinge.
Escherichia Coli O157 H7 Strain, supplied by DSMZ, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/escherichia coli o157 h7 strain/product/DSMZ
Average 97 stars, based on 1 article reviews
escherichia coli o157 h7 strain - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
glucophagetm  (Bristol Myers)
90
Bristol Myers glucophagetm
Microbial metabolomic pathway analysis and in vitro experiments. (A) The in vitro culture of B. longum or E. coli in the presence of excretory-secretory protein (ESP) (5 mg/ml) collected from different T. saginata tapeworm isolates ( n = 3 or 4). Colony-forming units (CFUs) were counted on plates ( n = 2 technical replicates for each sample). (B) PCoA using Bray–Curtis distance based on the relative abundances of MetaCyC pathways. (C) The pathways that were significantly increased in infection and negatively correlated with Bifidobacterium. The absolute value of the coefficient correlation between each pathway and the abundance of Bifidobacterium ( X -axis) and the coefficient in MaAsLin2 analysis (Y-axis) are shown. Only pathways with q value <0.05 in MaAsLin2 analysis were indicated with names. (D) The species with significantly differential abundance in the stachyose degradation pathway (the prevalence >0.1 and q value <0.25 after FDR correction) in MaAsLin2 analysis. The error bars indicate the 95% confidence intervals of coefficient estimates. (E) The negative correlations between B. longum and other species in the stachyose degradation pathway. The relative abundance was normalized by the centered log-ratio method. (F) In vitro growth rate of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of stachyose ( n = 3 replicates for each sample). (G) In vitro growth experiments of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of ESP ( n = 3 or 4 replicates). The data for panels A, F, and G are shown for mean ± SD, and P values for panels A and G were calculated by Student’s t -test. The R 2 statistic and P value for panel B were calculated by permutational multivariate analysis of variance (PERMANOVA). The box plot in panel B represents the 25th percentile, median, and 75th percentile and whiskers stretch to 1.5 times the interquartile range from the corresponding hinge.
Glucophagetm, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glucophagetm/product/Bristol Myers
Average 90 stars, based on 1 article reviews
glucophagetm - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
atcc 10813 gar  (ATCC)
94
ATCC atcc 10813 gar
Microbial metabolomic pathway analysis and in vitro experiments. (A) The in vitro culture of B. longum or E. coli in the presence of excretory-secretory protein (ESP) (5 mg/ml) collected from different T. saginata tapeworm isolates ( n = 3 or 4). Colony-forming units (CFUs) were counted on plates ( n = 2 technical replicates for each sample). (B) PCoA using Bray–Curtis distance based on the relative abundances of MetaCyC pathways. (C) The pathways that were significantly increased in infection and negatively correlated with Bifidobacterium. The absolute value of the coefficient correlation between each pathway and the abundance of Bifidobacterium ( X -axis) and the coefficient in MaAsLin2 analysis (Y-axis) are shown. Only pathways with q value <0.05 in MaAsLin2 analysis were indicated with names. (D) The species with significantly differential abundance in the stachyose degradation pathway (the prevalence >0.1 and q value <0.25 after FDR correction) in MaAsLin2 analysis. The error bars indicate the 95% confidence intervals of coefficient estimates. (E) The negative correlations between B. longum and other species in the stachyose degradation pathway. The relative abundance was normalized by the centered log-ratio method. (F) In vitro growth rate of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of stachyose ( n = 3 replicates for each sample). (G) In vitro growth experiments of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of ESP ( n = 3 or 4 replicates). The data for panels A, F, and G are shown for mean ± SD, and P values for panels A and G were calculated by Student’s t -test. The R 2 statistic and P value for panel B were calculated by permutational multivariate analysis of variance (PERMANOVA). The box plot in panel B represents the 25th percentile, median, and 75th percentile and whiskers stretch to 1.5 times the interquartile range from the corresponding hinge.
Atcc 10813 Gar, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atcc 10813 gar/product/ATCC
Average 94 stars, based on 1 article reviews
atcc 10813 gar - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti herp  (Proteintech)
93
Proteintech anti herp
Microbial metabolomic pathway analysis and in vitro experiments. (A) The in vitro culture of B. longum or E. coli in the presence of excretory-secretory protein (ESP) (5 mg/ml) collected from different T. saginata tapeworm isolates ( n = 3 or 4). Colony-forming units (CFUs) were counted on plates ( n = 2 technical replicates for each sample). (B) PCoA using Bray–Curtis distance based on the relative abundances of MetaCyC pathways. (C) The pathways that were significantly increased in infection and negatively correlated with Bifidobacterium. The absolute value of the coefficient correlation between each pathway and the abundance of Bifidobacterium ( X -axis) and the coefficient in MaAsLin2 analysis (Y-axis) are shown. Only pathways with q value <0.05 in MaAsLin2 analysis were indicated with names. (D) The species with significantly differential abundance in the stachyose degradation pathway (the prevalence >0.1 and q value <0.25 after FDR correction) in MaAsLin2 analysis. The error bars indicate the 95% confidence intervals of coefficient estimates. (E) The negative correlations between B. longum and other species in the stachyose degradation pathway. The relative abundance was normalized by the centered log-ratio method. (F) In vitro growth rate of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of stachyose ( n = 3 replicates for each sample). (G) In vitro growth experiments of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of ESP ( n = 3 or 4 replicates). The data for panels A, F, and G are shown for mean ± SD, and P values for panels A and G were calculated by Student’s t -test. The R 2 statistic and P value for panel B were calculated by permutational multivariate analysis of variance (PERMANOVA). The box plot in panel B represents the 25th percentile, median, and 75th percentile and whiskers stretch to 1.5 times the interquartile range from the corresponding hinge.
Anti Herp, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti herp/product/Proteintech
Average 93 stars, based on 1 article reviews
anti herp - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
holomog a 10813 s21250 ggcccauggaguuucugaatt ambion  (Thermo Fisher)
86
Thermo Fisher holomog a 10813 s21250 ggcccauggaguuucugaatt ambion
Microbial metabolomic pathway analysis and in vitro experiments. (A) The in vitro culture of B. longum or E. coli in the presence of excretory-secretory protein (ESP) (5 mg/ml) collected from different T. saginata tapeworm isolates ( n = 3 or 4). Colony-forming units (CFUs) were counted on plates ( n = 2 technical replicates for each sample). (B) PCoA using Bray–Curtis distance based on the relative abundances of MetaCyC pathways. (C) The pathways that were significantly increased in infection and negatively correlated with Bifidobacterium. The absolute value of the coefficient correlation between each pathway and the abundance of Bifidobacterium ( X -axis) and the coefficient in MaAsLin2 analysis (Y-axis) are shown. Only pathways with q value <0.05 in MaAsLin2 analysis were indicated with names. (D) The species with significantly differential abundance in the stachyose degradation pathway (the prevalence >0.1 and q value <0.25 after FDR correction) in MaAsLin2 analysis. The error bars indicate the 95% confidence intervals of coefficient estimates. (E) The negative correlations between B. longum and other species in the stachyose degradation pathway. The relative abundance was normalized by the centered log-ratio method. (F) In vitro growth rate of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of stachyose ( n = 3 replicates for each sample). (G) In vitro growth experiments of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of ESP ( n = 3 or 4 replicates). The data for panels A, F, and G are shown for mean ± SD, and P values for panels A and G were calculated by Student’s t -test. The R 2 statistic and P value for panel B were calculated by permutational multivariate analysis of variance (PERMANOVA). The box plot in panel B represents the 25th percentile, median, and 75th percentile and whiskers stretch to 1.5 times the interquartile range from the corresponding hinge.
Holomog A 10813 S21250 Ggcccauggaguuucugaatt Ambion, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/holomog a 10813 s21250 ggcccauggaguuucugaatt ambion/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
holomog a 10813 s21250 ggcccauggaguuucugaatt ambion - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier

Image Search Results


In vivo PAE of garenoxacin after administration of single doses of 16 and 64 mg/kg against S. pneumoniae ATCC 10813, S. aureus ATCC 6538p, and K. pneumoniae ATCC 43816. Each symbol represents the mean ± standard deviation for two mice. The widths of hollow bars represent the duration of time total serum levels exceeded the MIC for the infecting pathogen. The widths of the solid bars represent the duration of time free drug serum levels exceeded the MIC for the infecting pathogen.

Journal:

Article Title: Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model

doi: 10.1128/AAC.47.12.3935-3941.2003

Figure Lengend Snippet: In vivo PAE of garenoxacin after administration of single doses of 16 and 64 mg/kg against S. pneumoniae ATCC 10813, S. aureus ATCC 6538p, and K. pneumoniae ATCC 43816. Each symbol represents the mean ± standard deviation for two mice. The widths of hollow bars represent the duration of time total serum levels exceeded the MIC for the infecting pathogen. The widths of the solid bars represent the duration of time free drug serum levels exceeded the MIC for the infecting pathogen.

Article Snippet: These analyses suggest that treatment efficacy was dependent upon dose level and independent of the dosing intervals studied. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 3. caption a7 (a) The relationship between the garenoxacin dosing interval and efficacy against S. pneumoniae ATCC 10813 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. (b) The relationship between the garenoxacin dosing interval and efficacy against S. aureus ATCC 33591 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Dosing interval ED 25 (95% CI) a ED 50 (95% CI) ED 75 (95% CI) Static dose (95% CI) 1 log kill (95% CI) S. pneumoniae q3h 11.5 (8.2-14.8) 23 (16.3-29.7) 46.2 (32.8-59.6) 18.2 (12.9-23.5) 25.8 (18.3-33.3) q6h 8.3 (3.7-12.8) 18.4 (8.2-28.6) 41.1 (18.5-63.7) 16 (7.2-24.8) 25 (11.2-38.8) q12h 14.4 (0.6-28.2) 31 (0.7-61.3) 64 (3-125) 31 (0.7-61.3) 50.3 (23.3-78.3) q24h 12.9 (1.0-24.9) 38.8 (1.2-76.4) 115 (111-227) 65.7 (1.7-130) >128 S. aureus q3h 2.85 (2.6-3.1) 3.40 (3.1-3.8) 4.96 (4.5-5.5) 4.33 (3.9-4.8) 5.84 (5.3-6.4) q6h 1.05 (1.0-1.2) 4.07 (2.9-5.2) 15.9 (11.1-20.5) 10.0 (7.0-13.0) 30 (21.1-38.1) q12h 1.56 (1.4-1.8) 3.44 (3.0-3.8) 7.60 (6.7-8.5) 5.95 (5.0-7.0) 11.5 (10.1-12.9) q24h 2.9 (1.5-4.3) 7.46 (3.8-11.1) 19.1 (9.7-28.5) 7.91 (4.0-11.8) 26.6 (13.6-39.6) Open in a separate window a CI, confidence interval.

Techniques: In Vivo, Standard Deviation

(a) The relationship between the garenoxacin dosing interval and efficacy against S. pneumoniae ATCC 10813 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. (b) The relationship between the garenoxacin dosing interval and efficacy against S. aureus ATCC 33591 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs.

Journal:

Article Title: Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model

doi: 10.1128/AAC.47.12.3935-3941.2003

Figure Lengend Snippet: (a) The relationship between the garenoxacin dosing interval and efficacy against S. pneumoniae ATCC 10813 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. (b) The relationship between the garenoxacin dosing interval and efficacy against S. aureus ATCC 33591 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs.

Article Snippet: These analyses suggest that treatment efficacy was dependent upon dose level and independent of the dosing intervals studied. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 3. caption a7 (a) The relationship between the garenoxacin dosing interval and efficacy against S. pneumoniae ATCC 10813 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. (b) The relationship between the garenoxacin dosing interval and efficacy against S. aureus ATCC 33591 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Dosing interval ED 25 (95% CI) a ED 50 (95% CI) ED 75 (95% CI) Static dose (95% CI) 1 log kill (95% CI) S. pneumoniae q3h 11.5 (8.2-14.8) 23 (16.3-29.7) 46.2 (32.8-59.6) 18.2 (12.9-23.5) 25.8 (18.3-33.3) q6h 8.3 (3.7-12.8) 18.4 (8.2-28.6) 41.1 (18.5-63.7) 16 (7.2-24.8) 25 (11.2-38.8) q12h 14.4 (0.6-28.2) 31 (0.7-61.3) 64 (3-125) 31 (0.7-61.3) 50.3 (23.3-78.3) q24h 12.9 (1.0-24.9) 38.8 (1.2-76.4) 115 (111-227) 65.7 (1.7-130) >128 S. aureus q3h 2.85 (2.6-3.1) 3.40 (3.1-3.8) 4.96 (4.5-5.5) 4.33 (3.9-4.8) 5.84 (5.3-6.4) q6h 1.05 (1.0-1.2) 4.07 (2.9-5.2) 15.9 (11.1-20.5) 10.0 (7.0-13.0) 30 (21.1-38.1) q12h 1.56 (1.4-1.8) 3.44 (3.0-3.8) 7.60 (6.7-8.5) 5.95 (5.0-7.0) 11.5 (10.1-12.9) q24h 2.9 (1.5-4.3) 7.46 (3.8-11.1) 19.1 (9.7-28.5) 7.91 (4.0-11.8) 26.6 (13.6-39.6) Open in a separate window a CI, confidence interval.

Techniques: Infection

The relationships of the garenoxacin free drug 24-h AUC/MIC ratio, the percentage of the dosing interval that levels in serum remained above the MIC, and the peak/MIC ratio for S. pneumoniae ATCC 10813 with the log10 CFU/thigh after 24 h of therapy. Each symbol represents the mean data per mouse from two thighs. R2, coefficient of determination.

Journal:

Article Title: Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model

doi: 10.1128/AAC.47.12.3935-3941.2003

Figure Lengend Snippet: The relationships of the garenoxacin free drug 24-h AUC/MIC ratio, the percentage of the dosing interval that levels in serum remained above the MIC, and the peak/MIC ratio for S. pneumoniae ATCC 10813 with the log10 CFU/thigh after 24 h of therapy. Each symbol represents the mean data per mouse from two thighs. R2, coefficient of determination.

Article Snippet: These analyses suggest that treatment efficacy was dependent upon dose level and independent of the dosing intervals studied. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 3. caption a7 (a) The relationship between the garenoxacin dosing interval and efficacy against S. pneumoniae ATCC 10813 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. (b) The relationship between the garenoxacin dosing interval and efficacy against S. aureus ATCC 33591 in a murine thigh infection model. Each symbol represents the mean data per mouse from two thighs. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Dosing interval ED 25 (95% CI) a ED 50 (95% CI) ED 75 (95% CI) Static dose (95% CI) 1 log kill (95% CI) S. pneumoniae q3h 11.5 (8.2-14.8) 23 (16.3-29.7) 46.2 (32.8-59.6) 18.2 (12.9-23.5) 25.8 (18.3-33.3) q6h 8.3 (3.7-12.8) 18.4 (8.2-28.6) 41.1 (18.5-63.7) 16 (7.2-24.8) 25 (11.2-38.8) q12h 14.4 (0.6-28.2) 31 (0.7-61.3) 64 (3-125) 31 (0.7-61.3) 50.3 (23.3-78.3) q24h 12.9 (1.0-24.9) 38.8 (1.2-76.4) 115 (111-227) 65.7 (1.7-130) >128 S. aureus q3h 2.85 (2.6-3.1) 3.40 (3.1-3.8) 4.96 (4.5-5.5) 4.33 (3.9-4.8) 5.84 (5.3-6.4) q6h 1.05 (1.0-1.2) 4.07 (2.9-5.2) 15.9 (11.1-20.5) 10.0 (7.0-13.0) 30 (21.1-38.1) q12h 1.56 (1.4-1.8) 3.44 (3.0-3.8) 7.60 (6.7-8.5) 5.95 (5.0-7.0) 11.5 (10.1-12.9) q24h 2.9 (1.5-4.3) 7.46 (3.8-11.1) 19.1 (9.7-28.5) 7.91 (4.0-11.8) 26.6 (13.6-39.6) Open in a separate window a CI, confidence interval.

Techniques:

In vivo PAE of daptomycin against S. pneumoniae ATCC 10813 after administration of single doses of 2.5 (triangles) and 10 (squares) mg/kg. T > MIC, time that the concentration remains above the MIC.

Journal:

Article Title: In Vivo Pharmacodynamic Activity of Daptomycin

doi: 10.1128/AAC.48.1.63-68.2004

Figure Lengend Snippet: In vivo PAE of daptomycin against S. pneumoniae ATCC 10813 after administration of single doses of 2.5 (triangles) and 10 (squares) mg/kg. T > MIC, time that the concentration remains above the MIC.

Article Snippet: The low values for E. faecium may reflect the poor growth of the two strains of E. faecium in control mice (0.34 and 0.37 log 10 CFU/thigh over 24 h). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4. caption a7 Dose-response curves for daptomycin against various strains of S. pneumoniae . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 5. caption a7 Dose-response curves for daptomycin against various strains of S. aureus (circles) and E. faecium (squares). table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (mg/liter) Static dose (mg/kg/24 h) a 24-h AUC/MIC ratio Peak/MIC ratio Static dose 1 log killing 2 log killing Static dose 1 log killing 2 log killing S. pneumoniae ATCC 10813 0.12 2.16 168 390 582 25.1 48.2 86.5 S. pneumoniae CDC 145 0.12 0.954 74.7 108 157 11.8 16 23.4 S. pneumoniae CDC 1199 0.12 2.62 203 346 594 30.5 51.5 88.1 S. pneumoniae CDC 1396 0.12 1.5 117 150 190 17.4 22.3 28.3 S. pneumoniae CDC 673 0.12 3.05 237 467 815 35.5 69.5 121 S. pneumoniae CDC 1325 0.25 5.34 199 373 673 29.8 55.5 100 S. pneumoniae CDC 49619 0.25 4.9 182 337 703 27.3 50 104 S. pneumoniae CDC 1020 0.25 3.39 126 215 395 18.9 32 58.5 Mean ± SD (95% CI) for S. pneumoniae 160 ± 51 (72-316) 290 ± 121 (100-660) 498 ± 131 (117-813) 24 ± 7.6 (11-44) 42.1 ± 17.2 (15-98) 73.9 ± 34.2 (20-204) S. aureus ATCC 25923 0.5 20.8 388 594 896 59 109 197 S. aureus ATCC 33591 0.5 28.6 537 733 1,099 93.6 147 264 S. aureus ATCC 29213 0.5 22.5 420 588 788 66.2 107 163 S. aureus ATCC 6538p 0.5 21.9 409 750 1,460 63.6 152 398 Mean ± SD (95% CI) for S. aureus 438 ± 67 (316-550) 666 ± 87 (501-832) 1,061 ± 296 (603-1,738) 70.6 ± 15.6 (47-102) 129 ± 24.1 (86-184) 255 ± 104 (114-507) E. faecium VA 20 2 0.203 0.94 4.14 ND b 0.14 0.62 ND E. faecium VA 21 2 0.36 1.67 33.8 ND 0.25 5.05 ND Open in a separate window a Calculations are based on total drug levels.

Techniques: In Vivo, Concentration Assay

In vivo PAEs of free and total daptomycin concentrations of against S. aureus and S. pneumoniae

Journal:

Article Title: In Vivo Pharmacodynamic Activity of Daptomycin

doi: 10.1128/AAC.48.1.63-68.2004

Figure Lengend Snippet: In vivo PAEs of free and total daptomycin concentrations of against S. aureus and S. pneumoniae

Article Snippet: The low values for E. faecium may reflect the poor growth of the two strains of E. faecium in control mice (0.34 and 0.37 log 10 CFU/thigh over 24 h). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4. caption a7 Dose-response curves for daptomycin against various strains of S. pneumoniae . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 5. caption a7 Dose-response curves for daptomycin against various strains of S. aureus (circles) and E. faecium (squares). table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (mg/liter) Static dose (mg/kg/24 h) a 24-h AUC/MIC ratio Peak/MIC ratio Static dose 1 log killing 2 log killing Static dose 1 log killing 2 log killing S. pneumoniae ATCC 10813 0.12 2.16 168 390 582 25.1 48.2 86.5 S. pneumoniae CDC 145 0.12 0.954 74.7 108 157 11.8 16 23.4 S. pneumoniae CDC 1199 0.12 2.62 203 346 594 30.5 51.5 88.1 S. pneumoniae CDC 1396 0.12 1.5 117 150 190 17.4 22.3 28.3 S. pneumoniae CDC 673 0.12 3.05 237 467 815 35.5 69.5 121 S. pneumoniae CDC 1325 0.25 5.34 199 373 673 29.8 55.5 100 S. pneumoniae CDC 49619 0.25 4.9 182 337 703 27.3 50 104 S. pneumoniae CDC 1020 0.25 3.39 126 215 395 18.9 32 58.5 Mean ± SD (95% CI) for S. pneumoniae 160 ± 51 (72-316) 290 ± 121 (100-660) 498 ± 131 (117-813) 24 ± 7.6 (11-44) 42.1 ± 17.2 (15-98) 73.9 ± 34.2 (20-204) S. aureus ATCC 25923 0.5 20.8 388 594 896 59 109 197 S. aureus ATCC 33591 0.5 28.6 537 733 1,099 93.6 147 264 S. aureus ATCC 29213 0.5 22.5 420 588 788 66.2 107 163 S. aureus ATCC 6538p 0.5 21.9 409 750 1,460 63.6 152 398 Mean ± SD (95% CI) for S. aureus 438 ± 67 (316-550) 666 ± 87 (501-832) 1,061 ± 296 (603-1,738) 70.6 ± 15.6 (47-102) 129 ± 24.1 (86-184) 255 ± 104 (114-507) E. faecium VA 20 2 0.203 0.94 4.14 ND b 0.14 0.62 ND E. faecium VA 21 2 0.36 1.67 33.8 ND 0.25 5.05 ND Open in a separate window a Calculations are based on total drug levels.

Techniques: In Vivo

Static doses of daptomycin for different dosing intervals

Journal:

Article Title: In Vivo Pharmacodynamic Activity of Daptomycin

doi: 10.1128/AAC.48.1.63-68.2004

Figure Lengend Snippet: Static doses of daptomycin for different dosing intervals

Article Snippet: The low values for E. faecium may reflect the poor growth of the two strains of E. faecium in control mice (0.34 and 0.37 log 10 CFU/thigh over 24 h). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4. caption a7 Dose-response curves for daptomycin against various strains of S. pneumoniae . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 5. caption a7 Dose-response curves for daptomycin against various strains of S. aureus (circles) and E. faecium (squares). table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (mg/liter) Static dose (mg/kg/24 h) a 24-h AUC/MIC ratio Peak/MIC ratio Static dose 1 log killing 2 log killing Static dose 1 log killing 2 log killing S. pneumoniae ATCC 10813 0.12 2.16 168 390 582 25.1 48.2 86.5 S. pneumoniae CDC 145 0.12 0.954 74.7 108 157 11.8 16 23.4 S. pneumoniae CDC 1199 0.12 2.62 203 346 594 30.5 51.5 88.1 S. pneumoniae CDC 1396 0.12 1.5 117 150 190 17.4 22.3 28.3 S. pneumoniae CDC 673 0.12 3.05 237 467 815 35.5 69.5 121 S. pneumoniae CDC 1325 0.25 5.34 199 373 673 29.8 55.5 100 S. pneumoniae CDC 49619 0.25 4.9 182 337 703 27.3 50 104 S. pneumoniae CDC 1020 0.25 3.39 126 215 395 18.9 32 58.5 Mean ± SD (95% CI) for S. pneumoniae 160 ± 51 (72-316) 290 ± 121 (100-660) 498 ± 131 (117-813) 24 ± 7.6 (11-44) 42.1 ± 17.2 (15-98) 73.9 ± 34.2 (20-204) S. aureus ATCC 25923 0.5 20.8 388 594 896 59 109 197 S. aureus ATCC 33591 0.5 28.6 537 733 1,099 93.6 147 264 S. aureus ATCC 29213 0.5 22.5 420 588 788 66.2 107 163 S. aureus ATCC 6538p 0.5 21.9 409 750 1,460 63.6 152 398 Mean ± SD (95% CI) for S. aureus 438 ± 67 (316-550) 666 ± 87 (501-832) 1,061 ± 296 (603-1,738) 70.6 ± 15.6 (47-102) 129 ± 24.1 (86-184) 255 ± 104 (114-507) E. faecium VA 20 2 0.203 0.94 4.14 ND b 0.14 0.62 ND E. faecium VA 21 2 0.36 1.67 33.8 ND 0.25 5.05 ND Open in a separate window a Calculations are based on total drug levels.

Techniques:

Dose-response curves for daptomycin against various strains of S. pneumoniae.

Journal:

Article Title: In Vivo Pharmacodynamic Activity of Daptomycin

doi: 10.1128/AAC.48.1.63-68.2004

Figure Lengend Snippet: Dose-response curves for daptomycin against various strains of S. pneumoniae.

Article Snippet: The low values for E. faecium may reflect the poor growth of the two strains of E. faecium in control mice (0.34 and 0.37 log 10 CFU/thigh over 24 h). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4. caption a7 Dose-response curves for daptomycin against various strains of S. pneumoniae . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 5. caption a7 Dose-response curves for daptomycin against various strains of S. aureus (circles) and E. faecium (squares). table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (mg/liter) Static dose (mg/kg/24 h) a 24-h AUC/MIC ratio Peak/MIC ratio Static dose 1 log killing 2 log killing Static dose 1 log killing 2 log killing S. pneumoniae ATCC 10813 0.12 2.16 168 390 582 25.1 48.2 86.5 S. pneumoniae CDC 145 0.12 0.954 74.7 108 157 11.8 16 23.4 S. pneumoniae CDC 1199 0.12 2.62 203 346 594 30.5 51.5 88.1 S. pneumoniae CDC 1396 0.12 1.5 117 150 190 17.4 22.3 28.3 S. pneumoniae CDC 673 0.12 3.05 237 467 815 35.5 69.5 121 S. pneumoniae CDC 1325 0.25 5.34 199 373 673 29.8 55.5 100 S. pneumoniae CDC 49619 0.25 4.9 182 337 703 27.3 50 104 S. pneumoniae CDC 1020 0.25 3.39 126 215 395 18.9 32 58.5 Mean ± SD (95% CI) for S. pneumoniae 160 ± 51 (72-316) 290 ± 121 (100-660) 498 ± 131 (117-813) 24 ± 7.6 (11-44) 42.1 ± 17.2 (15-98) 73.9 ± 34.2 (20-204) S. aureus ATCC 25923 0.5 20.8 388 594 896 59 109 197 S. aureus ATCC 33591 0.5 28.6 537 733 1,099 93.6 147 264 S. aureus ATCC 29213 0.5 22.5 420 588 788 66.2 107 163 S. aureus ATCC 6538p 0.5 21.9 409 750 1,460 63.6 152 398 Mean ± SD (95% CI) for S. aureus 438 ± 67 (316-550) 666 ± 87 (501-832) 1,061 ± 296 (603-1,738) 70.6 ± 15.6 (47-102) 129 ± 24.1 (86-184) 255 ± 104 (114-507) E. faecium VA 20 2 0.203 0.94 4.14 ND b 0.14 0.62 ND E. faecium VA 21 2 0.36 1.67 33.8 ND 0.25 5.05 ND Open in a separate window a Calculations are based on total drug levels.

Techniques:

MICs, static doses, and magnitudes of 24-h AUC/MIC and peak/MIC ratios required to produce a bacteriostatic effect and killing of 1 and 2 log 10 CFU per thigh over 24 h

Journal:

Article Title: In Vivo Pharmacodynamic Activity of Daptomycin

doi: 10.1128/AAC.48.1.63-68.2004

Figure Lengend Snippet: MICs, static doses, and magnitudes of 24-h AUC/MIC and peak/MIC ratios required to produce a bacteriostatic effect and killing of 1 and 2 log 10 CFU per thigh over 24 h

Article Snippet: The low values for E. faecium may reflect the poor growth of the two strains of E. faecium in control mice (0.34 and 0.37 log 10 CFU/thigh over 24 h). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4. caption a7 Dose-response curves for daptomycin against various strains of S. pneumoniae . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 5. caption a7 Dose-response curves for daptomycin against various strains of S. aureus (circles) and E. faecium (squares). table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (mg/liter) Static dose (mg/kg/24 h) a 24-h AUC/MIC ratio Peak/MIC ratio Static dose 1 log killing 2 log killing Static dose 1 log killing 2 log killing S. pneumoniae ATCC 10813 0.12 2.16 168 390 582 25.1 48.2 86.5 S. pneumoniae CDC 145 0.12 0.954 74.7 108 157 11.8 16 23.4 S. pneumoniae CDC 1199 0.12 2.62 203 346 594 30.5 51.5 88.1 S. pneumoniae CDC 1396 0.12 1.5 117 150 190 17.4 22.3 28.3 S. pneumoniae CDC 673 0.12 3.05 237 467 815 35.5 69.5 121 S. pneumoniae CDC 1325 0.25 5.34 199 373 673 29.8 55.5 100 S. pneumoniae CDC 49619 0.25 4.9 182 337 703 27.3 50 104 S. pneumoniae CDC 1020 0.25 3.39 126 215 395 18.9 32 58.5 Mean ± SD (95% CI) for S. pneumoniae 160 ± 51 (72-316) 290 ± 121 (100-660) 498 ± 131 (117-813) 24 ± 7.6 (11-44) 42.1 ± 17.2 (15-98) 73.9 ± 34.2 (20-204) S. aureus ATCC 25923 0.5 20.8 388 594 896 59 109 197 S. aureus ATCC 33591 0.5 28.6 537 733 1,099 93.6 147 264 S. aureus ATCC 29213 0.5 22.5 420 588 788 66.2 107 163 S. aureus ATCC 6538p 0.5 21.9 409 750 1,460 63.6 152 398 Mean ± SD (95% CI) for S. aureus 438 ± 67 (316-550) 666 ± 87 (501-832) 1,061 ± 296 (603-1,738) 70.6 ± 15.6 (47-102) 129 ± 24.1 (86-184) 255 ± 104 (114-507) E. faecium VA 20 2 0.203 0.94 4.14 ND b 0.14 0.62 ND E. faecium VA 21 2 0.36 1.67 33.8 ND 0.25 5.05 ND Open in a separate window a Calculations are based on total drug levels.

Techniques:

AUC over 24 h for free daptomycin associated with the static dose and doses producing killing of 1 and 2 log10 CFU/thigh for multiple strains of S. pneumoniae and S. aureus.

Journal:

Article Title: In Vivo Pharmacodynamic Activity of Daptomycin

doi: 10.1128/AAC.48.1.63-68.2004

Figure Lengend Snippet: AUC over 24 h for free daptomycin associated with the static dose and doses producing killing of 1 and 2 log10 CFU/thigh for multiple strains of S. pneumoniae and S. aureus.

Article Snippet: The low values for E. faecium may reflect the poor growth of the two strains of E. faecium in control mice (0.34 and 0.37 log 10 CFU/thigh over 24 h). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4. caption a7 Dose-response curves for daptomycin against various strains of S. pneumoniae . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 5. caption a7 Dose-response curves for daptomycin against various strains of S. aureus (circles) and E. faecium (squares). table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (mg/liter) Static dose (mg/kg/24 h) a 24-h AUC/MIC ratio Peak/MIC ratio Static dose 1 log killing 2 log killing Static dose 1 log killing 2 log killing S. pneumoniae ATCC 10813 0.12 2.16 168 390 582 25.1 48.2 86.5 S. pneumoniae CDC 145 0.12 0.954 74.7 108 157 11.8 16 23.4 S. pneumoniae CDC 1199 0.12 2.62 203 346 594 30.5 51.5 88.1 S. pneumoniae CDC 1396 0.12 1.5 117 150 190 17.4 22.3 28.3 S. pneumoniae CDC 673 0.12 3.05 237 467 815 35.5 69.5 121 S. pneumoniae CDC 1325 0.25 5.34 199 373 673 29.8 55.5 100 S. pneumoniae CDC 49619 0.25 4.9 182 337 703 27.3 50 104 S. pneumoniae CDC 1020 0.25 3.39 126 215 395 18.9 32 58.5 Mean ± SD (95% CI) for S. pneumoniae 160 ± 51 (72-316) 290 ± 121 (100-660) 498 ± 131 (117-813) 24 ± 7.6 (11-44) 42.1 ± 17.2 (15-98) 73.9 ± 34.2 (20-204) S. aureus ATCC 25923 0.5 20.8 388 594 896 59 109 197 S. aureus ATCC 33591 0.5 28.6 537 733 1,099 93.6 147 264 S. aureus ATCC 29213 0.5 22.5 420 588 788 66.2 107 163 S. aureus ATCC 6538p 0.5 21.9 409 750 1,460 63.6 152 398 Mean ± SD (95% CI) for S. aureus 438 ± 67 (316-550) 666 ± 87 (501-832) 1,061 ± 296 (603-1,738) 70.6 ± 15.6 (47-102) 129 ± 24.1 (86-184) 255 ± 104 (114-507) E. faecium VA 20 2 0.203 0.94 4.14 ND b 0.14 0.62 ND E. faecium VA 21 2 0.36 1.67 33.8 ND 0.25 5.05 ND Open in a separate window a Calculations are based on total drug levels.

Techniques:

Microbial metabolomic pathway analysis and in vitro experiments. (A) The in vitro culture of B. longum or E. coli in the presence of excretory-secretory protein (ESP) (5 mg/ml) collected from different T. saginata tapeworm isolates ( n = 3 or 4). Colony-forming units (CFUs) were counted on plates ( n = 2 technical replicates for each sample). (B) PCoA using Bray–Curtis distance based on the relative abundances of MetaCyC pathways. (C) The pathways that were significantly increased in infection and negatively correlated with Bifidobacterium. The absolute value of the coefficient correlation between each pathway and the abundance of Bifidobacterium ( X -axis) and the coefficient in MaAsLin2 analysis (Y-axis) are shown. Only pathways with q value <0.05 in MaAsLin2 analysis were indicated with names. (D) The species with significantly differential abundance in the stachyose degradation pathway (the prevalence >0.1 and q value <0.25 after FDR correction) in MaAsLin2 analysis. The error bars indicate the 95% confidence intervals of coefficient estimates. (E) The negative correlations between B. longum and other species in the stachyose degradation pathway. The relative abundance was normalized by the centered log-ratio method. (F) In vitro growth rate of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of stachyose ( n = 3 replicates for each sample). (G) In vitro growth experiments of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of ESP ( n = 3 or 4 replicates). The data for panels A, F, and G are shown for mean ± SD, and P values for panels A and G were calculated by Student’s t -test. The R 2 statistic and P value for panel B were calculated by permutational multivariate analysis of variance (PERMANOVA). The box plot in panel B represents the 25th percentile, median, and 75th percentile and whiskers stretch to 1.5 times the interquartile range from the corresponding hinge.

Journal: The ISME Journal

Article Title: Taeniasis impacts human gut microbiome composition and function

doi: 10.1093/ismejo/wrae213

Figure Lengend Snippet: Microbial metabolomic pathway analysis and in vitro experiments. (A) The in vitro culture of B. longum or E. coli in the presence of excretory-secretory protein (ESP) (5 mg/ml) collected from different T. saginata tapeworm isolates ( n = 3 or 4). Colony-forming units (CFUs) were counted on plates ( n = 2 technical replicates for each sample). (B) PCoA using Bray–Curtis distance based on the relative abundances of MetaCyC pathways. (C) The pathways that were significantly increased in infection and negatively correlated with Bifidobacterium. The absolute value of the coefficient correlation between each pathway and the abundance of Bifidobacterium ( X -axis) and the coefficient in MaAsLin2 analysis (Y-axis) are shown. Only pathways with q value <0.05 in MaAsLin2 analysis were indicated with names. (D) The species with significantly differential abundance in the stachyose degradation pathway (the prevalence >0.1 and q value <0.25 after FDR correction) in MaAsLin2 analysis. The error bars indicate the 95% confidence intervals of coefficient estimates. (E) The negative correlations between B. longum and other species in the stachyose degradation pathway. The relative abundance was normalized by the centered log-ratio method. (F) In vitro growth rate of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of stachyose ( n = 3 replicates for each sample). (G) In vitro growth experiments of B. longum (left) and D. longicatena (right) in the presence of different concentrations (w/v) of ESP ( n = 3 or 4 replicates). The data for panels A, F, and G are shown for mean ± SD, and P values for panels A and G were calculated by Student’s t -test. The R 2 statistic and P value for panel B were calculated by permutational multivariate analysis of variance (PERMANOVA). The box plot in panel B represents the 25th percentile, median, and 75th percentile and whiskers stretch to 1.5 times the interquartile range from the corresponding hinge.

Article Snippet: The Dorea longicatena strain (DSM13814, DSMZ, German), B. longum strain (ATCC15707, Mingzhoubio, China), and Escherichia coli O157:H7 strain (ATCC700728, Biobw, China) were purchased from bioresource centers and cultured in modified PYG medium (DSMZ), GAM medium (Cat. HB8518, HopeBio, China), and LB medium at 37°C in anaerobic condition, respectively.

Techniques: In Vitro, Infection